Hannover Medical School
Clinical trials sponsored by Hannover Medical School, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could stem cell secretions protect hearing during implant surgery? Results expected Oct 2026 (estimated)
- Robotic seal aims to soothe Post-Surgery agitation Results expected Dec 2026 (estimated)
- Zapping two brain regions may ease Schizophrenia's toughest symptoms Results expected Dec 2026 (estimated)
- Tailored exercise may ease symptoms of rare blood cancer Results expected Dec 2026 (estimated)
- AI could help doctors personalize treatment for autoimmune hepatitis Results expected Jan 2027 (estimated)
-
Could stem cell secretions protect hearing during implant surgery?
Disease control OngoingThis early-stage trial tests whether a substance called VSF1.01, made from stem cell secretions, can safely reduce trauma to the inner ear during cochlear implant surgery. Eleven adults with severe hearing loss will receive the treatment directly into the cochlea before the impla…
Phase 1/2 • Sponsor: Hannover Medical School • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Diabetes drug repurposed to fight polycystic kidney disease
Disease control OngoingThis phase 4 trial tests whether empagliflozin, a diabetes drug, can safely slow kidney growth and preserve kidney function in 44 adults with rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). Participants take either empagliflozin or a placebo for 18 month…
Phase 4 • Sponsor: Hannover Medical School • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Massive lung screening trial aims to catch cancer early
Diagnosis OngoingThis study tests whether a lung cancer screening program can work effectively in Germany. Over 12,000 current or former smokers aged 55-79 will be screened using two different risk-based methods to see which finds more cancers early. The goal is to integrate screening into existi…
Sponsor: Hannover Medical School • Aim: Diagnosis
Last updated Jun 27, 2026 07:53 UTC
-
Hope for hepatitis delta patients: study seeks to end lifelong treatment
Knowledge-focused OngoingThis study looks at whether people with chronic hepatitis delta who have been on bulevirtide for at least 48 weeks and have very low virus levels can safely stop treatment. Researchers will monitor 20 participants for 48 weeks after stopping to find biological markers that predic…
Sponsor: Hannover Medical School • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
AI could help doctors personalize treatment for autoimmune hepatitis
Knowledge-focused OngoingThis study uses artificial intelligence to analyze data from 5,000 people with autoimmune hepatitis. The goal is to create a computer model that can predict which patients will respond well to standard therapy within 6 to 12 months. By identifying these patterns early, doctors ma…
Sponsor: Hannover Medical School • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Tiny study hopes antiviral drug eases dangerous liver pressure
Knowledge-focused OngoingThis observational study follows 11 patients with chronic hepatitis B and delta coinfection and liver cirrhosis who are already receiving the antiviral drug Bulevirtide. Researchers want to see if suppressing the virus reduces portal hypertension—a dangerous buildup of pressure i…
Sponsor: Hannover Medical School • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:20 UTC